期刊
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
卷 87, 期 4, 页码 743-753出版社
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.2012.12-0004
关键词
-
资金
- Research Development Foundation (Carson City, NV)
- North Carolina Agricultural Research Service
- Internal Revenue Service Therapeutic Discovery Project Grant for the State of North Carolina
- North Carolina Biotechnology Center (Research Triangle Park, NC)
The immunogenicity and safety of three novel host-range vaccines containing deletions in the transmembrane domain of dengue virus serotype 2 (DV2) E glycoprotein were evaluated in African green monkeys. The shorter transmembrane domains are capable of functionally spanning an insect but not a mammalian cell membrane, resulting in production of viral mutants that have reduced infectivity in mammalian hosts but efficient growth in insect cells. Groups of four monkeys received one dose each of test vaccine candidate with no booster immunization. After immunization, levels of viremia produced by each vaccine were determined by infectious center assay. Vaccine recipient immune response to wild-type DV2 challenge was measured on Day 57 by enzyme-linked immunosorbent assay and plaque reduction neutralization test. Two vaccines, DV2 Delta GVII and DV2G46013, generated neutralizing antibody in the range of 700-900 50% plaque reduction neutralization test units. All three vaccine strains decreased the length of viremia by at least two days. No safety concerns were identified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据